Presented by NUWA Fertility at the 2024 Taiwan Society for Reproductive Medicine (TSRM)
At the 2024 TSRM annual meeting, NUWA Fertility presented a study investigating whether the interval between trophectoderm biopsy and vitrification influences pregnancy outcomes for high-quality blastocysts (graded BB or above) that have undergone preimplantation genetic screening (PGS).
Background: Timing Considerations in Post-PGS Embryo Freezing
Preimplantation Genetic Screening (PGS) is a powerful tool for selecting chromosomally normal embryos, which improves IVF success rates.
During PGS, a trophectoderm biopsy is performed on the blastocyst. This study aimed to explore whether allowing the embryo to recover in culture for a few hours after biopsy, prior to freezing, might yield better pregnancy outcomes compared to immediate vitrification.
Key Finding: Delaying Freezing for 3+ Hours May Improve Pregnancy Rates
This retrospective study analyzed single euploid embryo transfers using PGS-normal embryos graded BB or above.
Preliminary results suggest that freezing the embryo more than 3 hours after biopsy may be associated with a higher pregnancy rate compared to embryos that were frozen immediately following biopsy.
This finding implies that a brief post-biopsy culture period may allow the embryo time to stabilize or recover, potentially improving post-thaw implantation potential.
However, the research team emphasized that larger-scale studies are needed to confirm this trend due to current sample size limitations.
Clinical Significance: A Potential Step Toward Optimizing Post-PGS Embryo Handling
These preliminary findings highlight a potential direction for optimizing lab protocols following PGS.
If future research confirms the benefits of extending culture time after biopsy, clinics may develop refined embryo handling workflows to further improve implantation and pregnancy success after PGS-based frozen embryo transfer.
NUWA Fertility continues to advance research in embryology and IVF optimization.
By translating the latest findings into clinical practice, we aim to offer patients higher-quality care and better outcomes throughout their fertility journey.